Postoperative pain is one of the key segments comprising the larger market for acute pain therapies. It has experienced strong growth over the past decade owing to the uptake of Pacira BioSciences’ Exparel in the United States. Nevertheless, unmet need remains for potent postoperative pain therapies that are not opioid analgesics and that can stave off persistent pain. Emerging therapies for moderate to severe postoperative pain will have to demonstrate convincing efficacy, safety, and convenience in multiple well-designed clinical trials and have these advantages translate into clinical practice. Given generic analgesics’ low price, wide availability, and entrenched position in the first-line treatment of postoperative pain, market access will be challenging for emerging postoperative pain therapies unless a strong value proposition is made.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for moderate to severe postoperative pain?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe postoperative pain?
- What are the prevailing areas of unmet need and market opportunity in moderate to severe postoperative pain?
- What trade-offs are acceptable to U.S. and European anesthesiologists for a hypothetical moderate to severe postoperative pain drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 31 European anesthesiologists
Key companies: Pacira BioSciences, Mallinckrodt Pharmaceuticals, Baudax Bio, AcelRx Pharmaceuticals, Trevena, Innocoll Pharmaceuticals, Heron Therapeutics, Durect
Key drugs: Exparel, Ofirmev, Anjeso, Dsuvia, Zalviso, Olinvyk, Xaracoll, Zynrelef (HTX-011), Posimir
CONTENT HIGHLIGHTS
- Target Product Profile (TPP) simulator based on conjoint analysis methodology
- Stated versus derived importance of product attributes on prescribing behavior
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Analysis of remaining drug development opportunities
- Postoperative Pain - Unmet Need - Detailed, Expanded Analysis : Postoperative Pain
- Executive Summary
- Unmet Need - Postoperative Pain - Executive Summary - March 2021
- Introduction
- Overview
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Products for Postoperative Pain and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed otAnesthesiologist / Anesthetists Prescribing Decisions in Postoperative Pain
- Importance of Efficacy Attributes to Prescribing Decisions in Postoperative Pain: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Postoperative Pain: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Postoperative Pain: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Postoperative Pain: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Postoperative Pain: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Postoperative Pain: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Postoperative Pain: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Postoperative Pain: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Postoperative Pain: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Postoperative Pain: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Postoperative Pain: United States
- Overall Performance of Key Therapies for Postoperative Pain: Europe
- Mean Overall Performance of Key Therapies for Postoperative Pain: United States and Europe
- Relative Performance of Key Therapies for Postoperative Pain Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Postoperative Pain Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Postoperative Pain Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Postoperative Pain Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Postoperative Pain Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Postoperative Pain Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Postoperative Pain Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Postoperative Pain Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Postoperative Pain
- Surveyed Anesthesiologist / Anesthetists Satisfaction with the Performance of Key Therapies for Postoperative Pain on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Anesthesiologist / Anesthetists Satisfaction with the Performance of Key Therapies for Postoperative Pain on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Efficacy Attributes in Postoperative Pain: United States
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Efficacy Attributes in Postoperative Pain: Europe
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Postoperative Pain: United States
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Postoperative Pain: Europe
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Postoperative Pain: United States
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Postoperative Pain: Europe
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Nonclinical Factors in Postoperative Pain: United States
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need Across Key Nonclinical Factors in Postoperative Pain: Europe
- Key Findings: Unmet Need in Postoperative Pain and Related Indications
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need in Postoperative Pain and Related Indications: United States
- Surveyed Anesthesiologist / Anesthetists Ascribed Level of Unmet Need in Postoperative Pain and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Postoperative Pain Market and Emerging Therapy Insights
- Opportunity: A Therapy That Reduces Postoperative Opioid Consumption
- Opportunity: A Therapy With a Lower Incidence of Treatment-Emergent Serious Adverse Events
- Opportunity: A Therapy With a Longer Duration of Action
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- Postoperative Pain Target Product Profile: Attribute Importance
- Efficacy For Reducing Postoperative Pain Intensity vs. Placebo
- Efficacy in Reducing Postoperative Opioid Consumption Over 24 Hours vs. Placebo
- Mean Incidence of Any Treatment-Emergent GI Adverse Events
- Incidence of Serious Treatment-Emergent Adverse Events
- Onset of Action
- Duration of Effect
- Price Per Unit / Vial
- Conjoint Analysis-Based Simulation of a Market Scenario
- Postoperative Pain Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- Postoperative Pain Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- Postoperative Pain Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Key Abbreviations
- Experts Interviewed
- Bibliography